| 摘要 |
Provided herein are pharmaceutical formulations comprising a one-armed, anti-c-met antibody, wherein the anti-c-met antibody comprises a HVR-L1 comprising sequence KSSQSLLYTSSQKNYLA (SEQ ID N0:1), a HVR-L2 comprising sequence WASTRES (SEQ ID NO: 2), a HVR-L3 comprising sequence QQYYAYPWT (SEQ ID N0:3), a HVR-HI comprising sequence GYTFTSYWLH (SEQ ID N0:4), a HVR-H2 comprising sequence GMIDPSNSDTRFNPNFKD (SEQ ID NO: 5), and a HVR-H3 comprising sequence ATYRSYVTPLDY (SEQ ID NO: 6); and uses of the same. |
